Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,303.67 +56.99 (+1.09%) Dow
39,854.48 +296.37 (+0.75%) Nasdaq
16,742.32 +231.14 (+1.40%) Bitcoin USD
65,957.09 +4,441.83 (+7.22%) CMC Crypto 200
1,381.72 +113.77 (+8.98%)
TEVA Jan 2025 4.000 call
| Previous close | 7.89 |
| Open | 7.89 |
| Bid | 8.85 |
| Ask | 9.40 |
| Strike | 4.00 |
| Expiry date | 2025-01-17 |
| Day's range | 7.89 - 7.89 |
| Contract range | N/A |
| Volume | |
| Open interest | 156 |
Business WireTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
TEL AVIV, Israel, May 15, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva’s Executive Leadership Team
ZacksIs Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.
ZacksShould Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
